Corvus Pharmaceuticals Inc (CRVS)
$5.64
+0.38
(+7.22%)▲
Performance
- $5.35$5.85$5.64
5.14%
Downside
Day's Volatility :8.55%
Upside
3.59%
- $1.05$6.15$5.64
81.38%
Downside
52 Weeks Volatility :82.93%
Upside
8.29%
Returns
| Period | Corvus Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 211.6% | 0.0% |
6 Months | 229.82% | 0.0% |
1 Year | 283.67% | 0.0% |
3 Years | 15.81% | -21.4% |
Highlights
Market Capitalization | 352.8M |
Book Value | $0.82 |
Earnings Per Share (EPS) | -0.43 |
PEG Ratio | 0.0 |
Wall Street Target Price | 10.13 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -23.83% |
Return On Equity TTM | -44.91% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -23.3M |
Diluted Eps TTM | -0.43 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.4 |
EPS Estimate Next Year | -0.46 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.12 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 79.61%
Technicals Summary
Sell
Neutral
Buy
Corvus Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Corvus Pharmaceuticals Inc | 29.24% | 229.82% | 283.67% | 15.81% | 104.35% |
 Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
 Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 71.74% | 59.21% | 32.07% | 248.13% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | NA | NA | 0.0 | -0.4 | -0.45 | -0.24 | NA | 0.82 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Corvus Pharmaceuticals Inc | Buy | $352.8M | 104.35% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Insights on Corvus Pharmaceuticals Inc
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 16.3%
Institutional Holdings
Orbimed Advisors, LLC
11.10%Samlyn Capital, LLC
9.79%Point72 Asset Management, L.P.
9.54%Adams Street Partners LLC
5.24%Vanguard Group Inc
2.64%Renaissance Technologies Corp
0.90%
Company Information
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Organization | Corvus Pharmaceuticals Inc |
Employees | 28 |
CEO | Dr. Richard A. Miller M.D. |
Industry | Health Technology |
Discover More
Generations Bancorp Ny Inc
$5.64
+7.22%
Utime Ltd
$5.64
+7.22%
Ncs Multistage Holdings Inc
$5.64
+7.22%
Rent The Runway, Inc
$5.64
+7.22%
Noodles & Co
$5.64
+7.22%
Aam Brentview Dividend Growth Etf
$5.64
+7.22%
Invesco Nasdaq Next Gen 100 Etf
$5.64
+7.22%
Cohen & Steers Tax-advantage
$5.64
+7.22%
Sim Acquisition Corp I-a
$5.64
+7.22%